Novartis Changing Of The Guard Continues As R&D Chief Bradner Exits
Merck & Co’s Marshall To Take Over
Executive Summary
A smooth handover hints at an amicable departure for Jay Bradner, but also gives CEO Vas Narasimhan the chance to refresh strategy with a new team.
You may also be interested in...
New Pure Play Novartis Vows To Up Its Game – With Help From In-House Challenger Ronny Gal
Having finally confirmed the Sandoz spin-off, Novartis will become a 'pure play' pharma company and focus on picking bigger blockbuster winners from both internal and external pipelines. CEO Vas Narasimhan talked details at an investor day in Basel.
No Cash Boost For Novartis From Sandoz Spin-Off
After a lengthy review, Novartis has confirmed Sandoz will be a publicly traded standalone company listed on the SIX Swiss Exchange, although CEO Vas Narasimhan says he will still consider bids for the division.
Dunad Bags Big Pharma Partner In Protein Degradation Deal With Novartis
Dunad is out-licensing its targeted protein degradation and covalent drug platform to Novartis in a deal that could be worth up to $1.3bn.